Literature DB >> 11222384

CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor.

M Bagot1, A Moretta, S Sivori, R Biassoni, C Cantoni, C Bottino, L Boumsell, A Bensussan.   

Abstract

Tumor cells of patients with cutaneous T-cell lymphoma (CTCL) have the cell surface phenotype of mature T-helper lymphocytes, and it may be impossible to differentiate them from nonmalignant lymphocytes in skin and blood. Until now, no specific cell membrane marker of CTCL has been reported. In the current study, it is reported for the first time that CTCL cells express the major histocompatibility complex class I binding p140-killer cell immunoglobulin-like receptor, which has been described on a minor subset of natural killer lymphocytes and on a marginal circulating CD8(+) T lymphocyte subset. Interestingly, the molecular characterization of this KIR expressed by CTCL allowed us to isolate a novel allelic form of p140-KIR3DL, resulting in 4 amino acid substitutions, 3 in the extracellular immunoglobulin-like domain of the protein and one in the cytoplasmic region. This finding is likely to be important both for the pathophysiology and for the clinical treatment of patients with CTCL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222384     DOI: 10.1182/blood.v97.5.1388

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Authors:  Hélène Sicard; Cécile Bonnafous; Ariane Morel; Martine Bagot; Armand Bensussan; Anne Marie-Cardine
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

2.  Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.

Authors:  Caroline Ram-Wolff; Nadine Martin-Garcia; Armand Bensussan; Martine Bagot; Nicolas Ortonne
Journal:  Am J Dermatopathol       Date:  2010-12       Impact factor: 1.533

3.  CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.

Authors:  Nicolas Ortonne; Sabine Le Gouvello; Hicham Mansour; Catherine Poillet; Nadine Martin; Marie-Hélène Delfau-Larue; Karen Leroy; Jean-Pierre Farcet; Martine Bagot; Armand Bensussan
Journal:  J Invest Dermatol       Date:  2007-08-16       Impact factor: 8.551

4.  TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.

Authors:  Audrey Gros; Elodie Laharanne; Marie Vergier; Martina Prochazkova-Carlotti; Anne Pham-Ledard; Thomas Bandres; Sandrine Poglio; Sabine Berhouet; Béatrice Vergier; Jean-Philippe Vial; Edith Chevret; Marie Beylot-Barry; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

5.  New Targeted Treatments for Cutaneous T-cell Lymphomas.

Authors:  Martine Bagot
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 6.  Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.

Authors:  Silke Heidenreich; Nicolaus Kröger
Journal:  Front Immunol       Date:  2017-02-08       Impact factor: 7.561

Review 7.  Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.

Authors:  Christian Schmitt; Anne Marie-Cardine; Armand Bensussan
Journal:  Front Immunol       Date:  2017-08-30       Impact factor: 7.561

Review 8.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

Review 9.  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.

Authors:  Tomonori Oka; Tomomitsu Miyagaki
Journal:  Front Med (Lausanne)       Date:  2019-05-29

10.  Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.

Authors:  Ieva Saulite; Desislava Ignatova; Yun-Tsan Chang; Christina Fassnacht; Florentia Dimitriou; Eleni Varypataki; Florian Anzengruber; Mirjam Nägeli; Antonio Cozzio; Reinhard Dummer; Julia Scarisbrick; Steve Pascolo; Wolfram Hoetzenecker; Malgorzata Bobrowicz; Emmanuella Guenova
Journal:  Oncoimmunology       Date:  2020-03-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.